Ultragenyx agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million, following FDA approval of its one-time gene therapy GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401. The transaction is structured as non-dilutive capital intended to fund the company’s broader rare and ultra-rare pipeline. The PRV framework can be redeemed for priority review of a later application or transferred to another company, and Ultragenyx is using the program in the same way it has previously benefited from prior voucher monetizations. The deal remains subject to customary closing conditions, including the HSR waiting period expiration—key for timing how quickly capital flows back into development and commercialization planning.